TABLE 1.
Clinical features and laboratory information of the participants.
| Microarray analysis | Validation | |||||
|---|---|---|---|---|---|---|
| RA | Control | RA | SLE | Control | OA | |
| (n = 5) | (n = 5) | (n = 49) | (n = 25) | (n = 40) | (n = 7) | |
| Age (years) | 45 (35–65) | 48 (32–68) | 51 (17–71) | 28 (16–40) | 50 (30–66) | 50 (49–54) |
| Sex (M/F) (n) | 2/3 | 2/3 | 18/31 | 7/18 | 14/26 | 2/5 |
| CRP (mg/L) | 65.2 (25.3–91.1) | NA | 23.8 (0.34–107.3) | 25.2 (0.1–113.5) | NA | 5 (0.5–10) |
| ESR (mm/1 h) | 59 (41–95) | NA | 38 (2.2–112) | 40 (9–102) | NA | 15 (7–23) |
| IgM RF(IU/mL) | 98.8 (60–411) | NA | 154.5 (9.19–4,700) | NA | NA | NA |
| Anti-CCP (U/mL) | 83.4 (30.1–450) | NA | 133.7 (7.8–1,200) | NA | NA | NA |
| DAS28 (scores) | 5.74 (5.08–7.25) | NA | 5.82 (3.08–8.16) | NA | NA | NA |
Abbreviations: RA: rheumatoid arthritis; SLE: systemic Lupus Erythematosus; OA: osteoarthritis; M/F: male/female; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: disease activity score in 28 joints; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide antibodies; NA: not available. Data are expressed as the median (range).